Genetic Technologies (GENE) Announces Settlement with AutoImmun Diagnostika GmbH
Tweet
Share
E-mailGet Alerts GENE Hot Sheet
Join SI Premium – FREE
Genetic Technologies Limited (NASDAQ: GENE) has now executed a Settlement and License Agreement with AutoImmun Diagnostika GmbH ("AID") of Strassberg, Germany.
Under the terms of the Agreement, AID is granted non-exclusive rights to a number of GTG patents relating to its non-coding DNA technology. As with other similar agreements, the precise commercial terms of the Agreement are covered by formal confidentiality provisions and cannot be disclosed.
Under the terms of the Agreement, AID is granted non-exclusive rights to a number of GTG patents relating to its non-coding DNA technology. As with other similar agreements, the precise commercial terms of the Agreement are covered by formal confidentiality provisions and cannot be disclosed.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Lazard Global Total Return fund declares $0.1534 monthly distribution
- Nu Skin EVP of global sales takes medical leave
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
